Other formats:
BibTeX
LaTeX
RIS
@article{2249114,
author = {Palmieri, LolaandJade and Buchler, Tomas and Meyer, Antoine and Veskrnova, Veronika and Fiala, Ondrej and Brabec, Petr and Baranová, Jana and Coriat, Romain},
article_location = {BASEL},
article_number = {6},
doi = {http://dx.doi.org/10.3390/cancers14061410},
keywords = {metastatic colorectal cancer; RAS status; anti-EGFR; bevacizumab},
language = {eng},
issn = {2072-6694},
journal = {Cancers},
title = {Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis},
url = {https://www.mdpi.com/2072-6694/14/6/1410},
volume = {14},
year = {2022}
}
TY - JOUR
ID - 2249114
AU - Palmieri, Lola-Jade - Buchler, Tomas - Meyer, Antoine - Veskrnova, Veronika - Fiala, Ondrej - Brabec, Petr - Baranová, Jana - Coriat, Romain
PY - 2022
TI - Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis
JF - Cancers
VL - 14
IS - 6
SP - 1-10
EP - 1-10
PB - MDPI
SN - 20726694
KW - metastatic colorectal cancer
KW - RAS status
KW - anti-EGFR
KW - bevacizumab
UR - https://www.mdpi.com/2072-6694/14/6/1410
N2 - Simple Summary The first-line therapy of patients with RAS wild-type (WT) non-resectable metastatic colorectal cancer (mCRC) is usually 5-fluorouracil-based chemotherapy with either bevacizumab or an anti-epidermal growth factor receptor (EGFR). The introduction of anti-epidermal growth factor antibodies is commonly delayed because of late RAS testing results. Our objective was to evaluate the impact on the overall survival of delayed anti-EGFR introduction strategy. This study compared 305 patients with delayed anti-EGFR introductions, 401 with immediate anti-EGFRs, and 129 with immediate anti-VEGFs. The study suggests that delayed introduction has no deleterious impact on survival compared to the immediate introduction of an anti-EGFR or of an anti-VEGF. The first-line therapy of patients with RAS wild-type (WT) non-resectable metastatic colorectal cancer (mCRC) is usually 5-fluorouracil-based chemotherapy with either bevacizumab or an anti-epidermal growth factor receptor (EGFR). The addition of anti-EGFR antibodies is commonly delayed in clinical practice because of late RAS testing results. Our objective was to evaluate the impact on overall survival (OS) of a delayed anti-EGFR introduction strategy. This study pooled the data of two large retrospective studies. Patients with RAS WT non-resectable mCRC, treated in first line by a doublet chemotherapy with an anti-EGFR introduced with a delay of 2 to 4 cycles, were compared to an anti-EGFR and to an anti-VEGF that was introduced immediately. Patients numbering 305 in the delayed anti-EGFR group, 401 in the immediate anti-EGFR group, and 129 in the immediate anti-VEGF group were analyzed. After propensity scoring, there was no difference between the characteristics of the three groups. Median OS was 28.6 months (95% CI: 23.5-34.1) in the immediate anti-EGFR group, 35.1 (95% CI: 29.9-43.5) in the delayed anti-EGFR group, and 32.4 (95% CI: 25.4-44.8) in the immediate anti-VEGF group. There was no significant difference concerning median OS (p = 0.24) or progression-free survival (p = 0.56). This study suggests that delaying the introduction of an anti-EGFR has no deleterious impact on survival compared to the immediate introduction of an anti-VEGF or of an anti-EGFR.
ER -
PALMIERI, Lola-Jade, Tomas BUCHLER, Antoine MEYER, Veronika VESKRNOVA, Ondrej FIALA, Petr BRABEC, Jana BARANOVÁ and Romain CORIAT. Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis. \textit{Cancers}. BASEL: MDPI, 2022, vol.~14, No~6, p.~1-10. ISSN~2072-6694. Available from: https://dx.doi.org/10.3390/cancers14061410.
|
